Press Releases AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Real-time Estimate Cboe BZX Other stock markets 04:03:20 2024-05-06 pm EDT			5-day change	1st Jan Change
75.24 ^USD	-1.46%		+0.33%	+12.44%

03:54pm	Cellectis: alliance with AstraZeneca finalized	CF
10:23am	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ANGLE PLC - NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA	10:42am	AQ
Combination treatment could provide new standard-of-care for aggressive lymphoma	May. 03	AQ
AI Startup Fileread Names Former AstraZeneca Legal Leader as Chief Strategy Officer and General Counsel to Drive Product Development and Accelerate Growth	May. 03	AQ
Astrazeneca - CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 03	AQ
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	May. 02	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 02	BU
Astrazeneca Joins Hands With Partners to Tackle Kenya's Cancer Burden	May. 01	AQ
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio	May. 01	BU
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition	Apr. 30	AQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow	Apr. 29	BU
Astrazeneca - Q1 2024 results	Apr. 26	AQ
Astrazeneca: Q1 Earnings Snapshot	Apr. 25	AQ
AlzeCure publishes its interim report for January – March 2024	Apr. 25	AQ
Q1 2024 results	Apr. 25	BU
Astrazeneca - Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia	Apr. 24	AQ
Prescient Healthcare Group Appoints Two New Members to its Board of Directors	Apr. 22	AQ
BRITAIN'S PROXY BATTLE REQUIRES A UNITED FRONT	Apr. 18	AQ
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials	Apr. 17	AQ
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	Apr. 17	AQ
Astrazeneca - New modelling reveals the escalating toll of chronic kidney disease on patients, planet and economies	Apr. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT